Regulation of striatal astrocytic receptor for advanced glycation end-products variants in an early stage of experimental Parkinson's disease

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 598-609

  Viana, Sofia D ^a,b,c   Valero, Jorge ^b,d,e   Rodrigues Santos, Paulo ^f,g   Couceiro, Patrícia ^g   Silva, Andréa M ^a,b   Carvalho, Félix ^h   Ali, Syed F ⁱ   Fontes Ribeiro, Carlos A ^a,b   Pereira, Frederico C ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c POLYTECHNIC INSTITUTE OF COIMBRA   (Portugal)

^d ACHUCARRO BASQUE CENTER FOR NEUROSCIENCE   (Spain)

^e BASQUE FOUNDATION FOR SCIENCE   (Spain)

^f UNIVERSITY OF COIMBRA   (Portugal)

^g UNIVERSITY OF COIMBRA   (Portugal)

^h UNIVERSITY OF PORTO   (Portugal)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

astrocytes; MPTP; RAGE isoforms; S100B; striatum

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROTEIN; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL ACTIVITY; CELL BODY; CELL DENSITY; CELL PROTECTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DENERVATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL PARKINSONISM; GENE; GENE CONTROL; GENE MAPPING; GENETIC VARIATION; GLIA CELL; GLIOSIS; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INFLAMMATION; MALE; MOLECULAR DYNAMICS; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONTENT; RAGE GENE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; STRIATED MUSCLE CELL; UPREGULATION;

EID: 84981172818     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13682     Document Type: Article

References (62)

1. Abdelsalam R. M. and Safar M. M. (2015) Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFkappaB and Nrf2-antioxidant signaling pathways. J. Neurochem. 133, 700–707.
2. Adami C., Bianchi R., Pula G. and Donato R. (2004) S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain. Biochim. Biophys. Acta 1742, 169–177.
3. Alexiou P., Chatzopoulou M., Pegklidou K. and Demopoulos V. J. (2010) RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr. Med. Chem. 17, 2232–2252.
4. Anzilotti S., Giampa C., Laurenti D., Perrone L., Bernardi G., Melone M. A. and Fusco F. R. (2012) Immunohistochemical localization of receptor for advanced glycation end (RAGE) products in the R6/2 mouse model of Huntington's disease. Brain Res. Bull. 87, 350–358.
5. van Beijnum J. R., Buurman W. A. and Griffioen A. W. (2008) Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11, 91–99.
6. Bierhaus A. and Nawroth P. P. (2009) Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52, 2251–2263.
7. Chen P. C., Vargas M. R., Pani A. K., Smeyne R. J., Johnson D. A., Kan Y. W. and Johnson J. A. (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc. Natl Acad. Sci. USA 106, 2933–2938.
8. Choi Y. G. and Lim S. (2010) N(varepsilon)-(carboxymethyl)lysine linkage to alpha-synuclein and involvement of advanced glycation end products in alpha-synuclein deposits in an MPTP-intoxicated mouse model. Biochimie 92, 1379–1386.
9. Chung Y. C., Kim Y. S., Bok E., Yune T. Y., Maeng S. and Jin B. K. (2013) MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. Mediators Inflamm. 2013, 370526.
10. Coelho-Santos V., Leitao R. A., Cardoso F. L., Palmela I., Rito M., Barbosa M., Brito M. A., Fontes-Ribeiro C. A. and Silva A. P. (2015) The TNF-alpha/NF-kappaB signaling pathway has a key role in methamphetamine-induced blood-brain barrier dysfunction. J. Cereb. Blood Flow Metab. 35, 1260–1271.
11. Daffu G., del Pozo C. H., O'Shea K. M., Ananthakrishnan R., Ramasamy R. and Schmidt A. M. (2013) Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int. J. Mol. Sci. 14, 19891–19910.
12. Dalfo E., Portero-Otin M., Ayala V., Martinez A., Pamplona R. and Ferrer I. (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropathol. Exp. Neurol. 64, 816–830.
13. Dauer W. and Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889–909.
14. Di Monte D. A., Wu E. Y., Delanney L. E., Irwin I. and Langston J. W. (1992) Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. J. Pharmacol. Exp. Ther. 261, 44–49.
15. Ding Q. and Keller J. N. (2005) Evaluation of rage isoforms, ligands, and signaling in the brain. Biochim. Biophys. Acta 1746, 18–27.
16. Donato R., Sorci G., Riuzzi F., Arcuri C., Bianchi R., Brozzi F., Tubaro C. and Giambanco I. (2009) S100B's double life: intracellular regulator and extracellular signal. Biochim. Biophys. Acta 1793, 1008–1022.
17. Fernandez-Gonzalez A., Perez-Otano I. and Morgan J. I. (2000) MPTP selectively induces haem oxygenase-1 expression in striatal astrocytes. Eur. J. Neuorsci. 12, 1573–1583.
18. Galichet A., Weibel M. and Heizmann C. W. (2008) Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem. Biophys. Res. Commun. 370, 1–5.
19. Greco R., Amantea D., Mangione A. S., Petrelli F., Gentile R., Nappi G., Blandini F., Corasaniti M. T. and Tassorelli C. (2012) Modulation of RAGE isoforms expression in the brain and plasma of rats exposed to transient focal cerebral ischemia. Neurochem. Res. 37, 1508–1516.
20. Herold K., Moser B., Chen Y., Zeng S., Yan S. F., Ramasamy R., Emond J., Clynes R. and Schmidt A. M. (2007) Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol. 82, 204–212.
21. Himeda T., Watanabe Y., Tounai H., Hayakawa N., Kato H. and Araki T. (2006) Time dependent alterations of co-localization of S100beta and GFAP in the MPTP-treated mice. J. Neural. Transm. 113, 1887–1894.
22. Huang M., Que Y. and Shen X. (2015) Correlation of the plasma levels of soluble RAGE and endogenous secretory RAGE with oxidative stress in pre-diabetic patients. J. Diabetes Complications 29, 422–426.
23. Hudson B. I., Carter A. M., Harja E., Kalea A. Z., Arriero M., Yang H., Grant P. J. and Schmidt A. M. (2008) Identification, classification, and expression of RAGE gene splice variants. FASEB J. 22, 1572–1580.
24. Hunot S. and Hirsch E. C. (2003) Neuroinflammatory processes in Parkinson's disease. Ann. Neurol., 53(Suppl 3), S49–S58; discussion S58-60.
25. Jackson-Lewis V., Jakowec M., Burke R. E. and Przedborski S. (1995) Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4, 257–269.
26. Langston J. W. and Irwin I. (1986) MPTP: current concepts and controversies. Clin. Neuropharmacol. 9, 485–507.
27. Leclerc E., Fritz G., Vetter S. W. and Heizmann C. W. (2009) Binding of S100 proteins to RAGE: an update. Biochim. Biophys. Acta 1793, 993–1007.
28. Li H., Wu W., Sun Q., Liu M., Li W., Zhang X. S., Zhou M. L. and Hang C. H. (2014) Expression and cell distribution of receptor for advanced glycation end-products in the rat cortex following experimental subarachnoid hemorrhage. Brain Res. 1543, 315–323.
29. Lopez-Diez R., Rastrojo A., Villate O. and Aguado B. (2013) Complex tissue-specific patterns and distribution of multiple RAGE splice variants in different mammals. Genome Biol. Evol. 5, 2420–2435.
30. Mandir A. S., Przedborski S., Jackson-Lewis V. et al. (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc. Natl Acad. Sci. USA 96, 5774–5779.
31. Marinelli C., Di Liddo R., Facci L., Bertalot T., Conconi M. T., Zusso M., Skaper S. D. and Giusti P. (2015) Ligand engagement of Toll-like receptors regulates their expression in cortical microglia and astrocytes. J. Neuroinflammation 12, 244.
32. Meneghini V., Bortolotto V., Francese M. T., Dellarole A., Carraro L., Terzieva S. and Grilli M. (2013) High-mobility group box-1 protein and beta-amyloid oligomers promote neuronal differentiation of adult hippocampal neural progenitors via receptor for advanced glycation end products/nuclear factor-kappaB axis: relevance for Alzheimer's disease. J. Neurosci. 33, 6047–6059.
33. Muramatsu Y., Kurosaki R., Watanabe H., Michimata M., Matsubara M., Imai Y. and Araki T. (2003) Expression of S-100 protein is related to neuronal damage in MPTP-treated mice. Glia 42, 307–313.
34. Mythri R. B., Venkateshappa C., Harish G., Mahadevan A., Muthane U. B., Yasha T. C., Srinivas Bharath M. M. and Shankar S. K. (2011) Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem. Res. 36, 1452–1463.
35. Noelker C., Morel L., Lescot T. et al. (2013) Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci. Rep. 3, 1393.
36. O'Callaghan J. P., Sriram K. and Miller D. B. (2008) Defining “neuroinflammation”. Ann. N. Y. Acad. Sci. 1139, 318–330.
37. Ookubo M., Yokoyama H., Kato H. and Araki T. (2009) Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice. Mol. Cell. Endocrinol. 311, 62–68.
38. Panicker N., Saminathan H., Jin H. et al. (2015) Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease. J. Neurosci. 35, 10058–10077.
39. Pattarini R., Rong Y., Qu C. and Morgan J. I. (2008) Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum. Neuroscience 155, 1174–1194.
40. Paxinos G. and Franklin K. B. J. (2004) The Mouse Brain in Stereotaxic Coordinates. Elsevier Academic Press, Amsterdam; Boston.
41. Peng J. and Andersen J. K. (2011) Mutant alpha-synuclein and aging reduce neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Aging Cell 10, 255–262.
42. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V. L. and Dawson T. M. (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl Acad. Sci. USA 93, 4565–4571.
43. Przedborski S., Jackson-Lewis V., Naini A. B., Jakowec M., Petzinger G., Miller R. and Akram M. (2001) The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76, 1265–1274.
44. Qin J., Goswami R., Dawson S. and Dawson G. (2008) Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J. Neurosci. Res. 86, 2414–2422.
45. Rojas A., Figueroa H. and Morales E. (2010) Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 31, 334–341.
46. Ros-Bernal F., Hunot S., Herrero M. T. et al. (2011) Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc. Natl Acad. Sci. USA 108, 6632–6637.
47. Santoro M., Maetzler W., Stathakos P. et al. (2016) In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. Neurobiol. Dis. 91, 59–68.
48. Sathe K., Maetzler W., Lang J. D. et al. (2012) S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain 135, 3336–3347.
49. Schaf D. V., Tort A. B., Fricke D., Schestatsky P., Portela L. V., Souza D. O. and Rieder C. R. (2005) S100B and NSE serum levels in patients with Parkinson's disease. Parkinsonism Relat. Disord. 11, 39–43.
50. Silva C. D., Neves A. F., Dias A. I. et al. (2014) A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice. Neurotox. Res. 25, 295–304.
51. Smeyne R. J. and Jackson-Lewis V. (2005) The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 134, 57–66.
52. Sorci G., Giovannini G., Riuzzi F., Bonifazi P., Zelante T., Zagarella S., Bistoni F., Donato R. and Romani L. (2011) The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation. PLoS Pathog. 7, e1001315.
53. Sorci G., Riuzzi F., Giambanco I. and Donato R. (2013) RAGE in tissue homeostasis, repair and regeneration. Biochim. Biophys. Acta 1833, 101–109.
54. Teismann P., Sathe K., Bierhaus A., Leng L., Martin H. L., Bucala R., Weigle B., Nawroth P. P. and Schulz J. B. (2012) Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiol. Aging 33, 2478–2490.
55. Viana S. D., Fernandes R. C., Canas P. M., Silva A. M., Carvalho F., Ali S. F., Fontes Ribeiro C. A. and Pereira F. C. (2016) Presymptomatic MPTP Mice Show Neurotrophic S100B/mRAGE Striatal Levels. CNS Neurosci. Ther. 22, 396–403.
56. Villarreal A., Seoane R., Gonzalez Torres A., Rosciszewski G., Angelo M. F., Rossi A., Barker P. A. and Ramos A. J. (2014) S100B protein activates a RAGE-dependent autocrine loop in astrocytes: implications for its role in the propagation of reactive gliosis. J. Neurochem. 131, 190–205.
57. Wang Y. R., Qin S., Han R., Wu J. C., Liang Z. Q., Qin Z. H. and Wang Y. (2013) Cathepsin L plays a role in quinolinic acid-induced NF-Kappab activation and excitotoxicity in rat striatal neurons. PLoS ONE 8, e75702.
58. Wong S. S., Li R. H. and Stadlin A. (1999) Oxidative stress induced by MPTP and MPP(+): selective vulnerability of cultured mouse astrocytes. Brain Res. 836, 237–244.
59. Wu D. C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H. and Przedborski S. (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl Acad. Sci. USA 100, 6145–6150.
60. Yan S. F., Ramasamy R. and Schmidt A. M. (2010) Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem. Pharmacol. 79, 1379–1386.
61. Yasuda Y., Shimoda T., Uno K., Tateishi N., Furuya S., Yagi K., Suzuki K. and Fujita S. (2008) The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J. Neuroimmunol. 204, 43–51.
62. Zurolo E., Iyer A., Maroso M. et al. (2011) Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain 134, 1015–1032.